Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
Joint Authors
Khammari, A.
Knol, Anne-Chantal
Pandolfino, Marie-Christine
Quéreux, Gaëlle
Saint-Jean, Mélanie
Volteau, Christelle
Peuvrel, Lucie
Brocard, Anabelle
Nguyen, Jean-Michel
Bedane, Christophe
Basset-Seguin, Nicole
Saïagh, S.
Dreno, B.
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-03-19
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs).
This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma.
All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included.
After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regimen.
Nine women and 1 man were treated for unresectable stage IIIC (n=4) or IV (n=6) melanoma.
All but 1 patient with unresectable stage III melanoma (1st line) had received at least 2 previous treatments, including anti-CTLA-4 antibody for 4.
The number of TILs infused ranged from 0.23 × 109 to 22.9 × 109.
Regarding safety, no serious adverse effect was reported.
Therapeutic responses included a complete remission, a partial remission, 2 stabilizations, and 6 progressions.
Among these 4 patients with clinical benefit, 1 is still alive with 9 years of follow-up and 1 died from another cause after 8 years of follow-up.
Notably, patients treated with high percentages of CD4 + CD25 + CD127lowFoxp3+ T cells among their TILs had significantly shorter OS.
The therapeutic effect of combining TILs with new immunotherapies needs further investigation.
American Psychological Association (APA)
Saint-Jean, Mélanie& Knol, Anne-Chantal& Volteau, Christelle& Quéreux, Gaëlle& Peuvrel, Lucie& Brocard, Anabelle…[et al.]. 2018. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1192116
Modern Language Association (MLA)
Saint-Jean, Mélanie…[et al.]. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. Journal of Immunology Research No. 2018 (2018), pp.1-10.
https://search.emarefa.net/detail/BIM-1192116
American Medical Association (AMA)
Saint-Jean, Mélanie& Knol, Anne-Chantal& Volteau, Christelle& Quéreux, Gaëlle& Peuvrel, Lucie& Brocard, Anabelle…[et al.]. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1192116
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1192116